Vertex’s Orkambi receives EC approval
Orkambi is an oral treatment for very young children that combines both lumacaftor and ivacaftor
Read Moreby John Pinching | Jul 5, 2023 | News | 0
Orkambi is an oral treatment for very young children that combines both lumacaftor and ivacaftor
Read Moreby John Pinching | Jun 7, 2022 | News | 0
New data now reveals significant increases in the blood glucose time-in-range compared to baseline, following VX-880 dosage
Read Moreby Lucy Parsons | Nov 15, 2021 | News | 0
Those eligible will have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
Read Moreby Lucy Parsons | Jun 14, 2021 | News | 0
CTX001 is being evaluated as a one-time treatment for transfusion dependent beta thalassemia and sickle cell disease
Read Moreby Selina McKee | May 20, 2021 | News | 0
If approved, up to 2,000 children with CF would be eligible for treatment with the drug
Read Moreby Lucy Parsons | May 11, 2021 | News | 0
Extension of indication expands access to drug for additional cystic fibrosis patients in Great Britain
Read Moreby Lucy Parsons | Apr 29, 2021 | News | 0
Extension means the ‘majority’ of people aged 12 years and older with CF in Europe can now access therapy
Read Moreby Selina McKee | Nov 27, 2020 | News | 0
The combination is the first available to treat the underlying cause of CF in this patient group.
Read Moreby Selina McKee | Jul 23, 2020 | News | 0
The letter of intent should secure access to the combination for people with cystic fibrosis upon its regulatory approval
Read Moreby Selina McKee | Jul 1, 2020 | News | 0
CF patients in England will be among the first in Europe to benefit from access to Kaftrio, if the medicine is approved by the EC
Read Moreby Selina McKee | Jun 29, 2020 | News | 0
The recommendations include a conditional approval for Gilead’s Veklury (remdesivir) for COVID-19
Read Moreby Selina McKee | Jun 10, 2020 | News | 0
Kalydeco is the only approved medicine in Europe to treat the underlying cause of cystic fibrosis in patients with the R117H mutation
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479